{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:49:37Z","timestamp":1790858977652,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jaci.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T09:01:26Z","timestamp":1488531686000},"page":"726-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing"],"prefix":"10.1016","volume":"139","author":[{"given":"Donald B.","family":"Kohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Y.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.01.007_bib1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.01.007_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM197804272981701","article-title":"Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation","volume":"298","author":"Parkman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib3","first-page":"980","article-title":"Improved retroviral vectors for gene transfer and expression","volume":"7","author":"Miller","year":"1989","journal-title":"Biotechniques"},{"key":"10.1016\/j.jaci.2017.01.007_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.01.007_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0092-8674(85)80102-1","article-title":"Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W\/Wv mice","volume":"42","author":"Dick","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.01.007_bib6","first-page":"1065","article-title":"Retroviral vector-mediated gene transfer into primitive human hematopoietic progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines","volume":"20","author":"Nolta","year":"1992","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaci.2017.01.007_bib7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1172\/JCI117122","article-title":"Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors","volume":"93","author":"Moritz","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.01.007_bib8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib9","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase\u2013deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.01.007_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.01.007_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib13","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.01.007_bib14","first-page":"S107","article-title":"Phase II clinical trial of gene therapy for adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID)","volume":"22","author":"Candotti","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex\u00a0vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.01.007_bib19","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal t cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib20","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.01.007_bib22","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib26","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJM200406103502422","article-title":"LMO2 and gene therapy for severe combined immunodeficiency","volume":"350","author":"Fischer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib27","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.01.007_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib29","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2014long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In\u00a0vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aah6192","article-title":"Lentiviral vectors, two decades later","volume":"353","author":"Naldini","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib32","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/mt.2013.265","article-title":"Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency","volume":"22","author":"Carbonaro","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2009.31","article-title":"Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models","volume":"17","author":"Marangoni","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.gt.3302863","article-title":"Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients","volume":"14","author":"Charrier","year":"2007","journal-title":"Gene Therapy"},{"key":"10.1016\/j.jaci.2017.01.007_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.01.007_bib37","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S1525-0016(16)33866-7","article-title":"Immunological and metabolic correction after lentiviral vector gene therapy for ADA deficiency","volume":"23","author":"Gaspar","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib38","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-Linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib39","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib40","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2017.01.007_bib41","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib42","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI31666","article-title":"Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy","volume":"117","author":"Aiuti","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.01.007_bib43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.1078395","article-title":"Chimeric nucleases stimulate gene targeting in human cells","volume":"300","author":"Porteus","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nbt1353","article-title":"Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery","volume":"25","author":"Lombardo","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.01.007_bib47","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/mt.2013.106","article-title":"Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus","volume":"21","author":"Joglekar","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib48","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease","volume":"34","author":"De Ravin","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.01.007_bib49","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S1525-0016(16)33563-8","article-title":"One-time gene therapy for hereditary angioedema","volume":"24","author":"Pagovich","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.01.007_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.01.007_bib51","doi-asserted-by":"crossref","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.01.007_bib52","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.01.007_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/mt.2014.195","article-title":"An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease","volume":"23","author":"Merling","year":"2015","journal-title":"Mol Ther"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917301458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917301458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:02:39Z","timestamp":1758790959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917301458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0091674917301458"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.01.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}